Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Are you mad just because you are a moron ?

  • Continued.....
    "..........The work began several years ago when researchers at the Broad Institute of Harvard and M.I.T. started searching through an enormous data set — drawn from 70 studies involving 200,000 people — to see if there were tiny genetic changes near or in genes that seemed to lead to very high or very low amounts of triglycerides in the blood. They also asked whether people who happened to have a higher or lower triglyceride level also had a higher or lower incidence of heart attacks.

    The researchers discovered that people with a genetic predisposition to higher triglyceride levels had more heart attacks and those with genetically lower triglyceride levels had fewer."

  • From 2014

    "Two major studies by leading research groups published on Wednesday independently identified mutations in a single gene that protect against heart attacks by keeping levels of triglycerides — a kind of fat in the blood — very low for a lifetime.

    The findings are expected to lead to a push to develop drugs that mimic the effect of the mutations, potentially offering the first new class of drugs to combat heart disease in decades, experts say. Statins, which reduce LDL cholesterol, another cause of heart disease, became blockbusters in the late 1980s. Since then, there have been no major new drugs approved for lowering heart disease risk. But experts caution that drug development takes years...."
    ----------------------
    The above is a great reason to look for combo pills in the future and perhaps the reason Amarin has to literally force its product on the market. Most innovations in drugs are done by small biotech companies as big pharma search for M/A victims. Amarin to date has refused to be victimized and are very close to proving their concept.

  • Reply to

    13G just filed by Stonepine capital

    by pg135788 Feb 12, 2016 6:13 PM

    Some former major holders waiting on the sidelines until R- it clarity. It is what it is, but the science will prevail in the end.

  • Are you mad that your moronic questions go unanswered?

  • Reply to

    13G just filed by Stonepine capital

    by pg135788 Feb 12, 2016 6:13 PM

    They don't hold AMRN. They reported 0 share ownership as of 12/31/2015. They owned 11m shares at 12/31/2014.

  • I have to question your motives here centless. Are you a hired pumper? Per your own addmision this is an old article. Nobody here or in the medical world has questioned vascepas safety profile or effectiveness. What you have here up to this point is a case of a good drug doesn't always coralate into a selling drug or a good stock. That can't be argued. Sales have been paltry and quite frankly the stock has sucked for 3 years. You pumpers can't or won't look at at all angles because you are married and emotionally attached to this ticker. I have made several traded recently here at a gains even when the story has been bad because I know when to fold them. I can't understand for the life of me why you are posting these useless threads that are old and everyone already knows about other then some sort of agenda.

  • Perhaps this excerpt from an older article helps explains why:

    "Those studies, published in The New England Journal of Medicine and funded by the National Institutes of Health and the European Union, provide “a very, very strong type of evidence,” Dr. Hegele said, that triglycerides are in fact a cause of heart attacks.

    The work began several years ago when researchers at the Broad Institute of Harvard and M.I.T. started searching through an enormous data set — drawn from 70 studies involving 200,000 people — to see if there were tiny genetic changes near or in genes that seemed to lead to very high or very low amounts of triglycerides in the blood. They also asked whether people who happened to have a higher or lower triglyceride level also had a higher or lower incidence of heart attacks.

    The researchers discovered that people with a genetic predisposition to higher triglyceride levels had more heart attacks and those with genetically lower triglyceride levels had fewer."

  • Reply to

    13G just filed by Stonepine capital

    by pg135788 Feb 12, 2016 6:13 PM

    How do you know they filed a 13 g? If you have found the filing you will find your answer. I am surprised they are still holding their shares in Amarin. They had about 1/3 of their total portfolio invested in Amarin. That is a huge bet for them particularly when Amarin's future is coming down to results in the R-it trial. I have confidence that Vascepa will prove its efficacy combined with statins to improve benefits significantly, but I have nowhere near the amount of money or percentage of my portfolio riding on this trial so I couldn't blame them, particularly with the SP falling, for waiting on the sidelines. They could have possibly gotten out in Dec. because of the frustrations of the extension of settlement talks to Feb. And IMO if it is indeed extended again that will more than prove that all of these manipulations have to do with R-it. But as time goes by it ( the longer it takes to reach the 967th event) only proves that Vascepa is efficacious in helping to prevent CVE. Some statisticians have noted that a placebo rate of 5% as of Jan. 11th 2016 would indicate a relative risk reduction ( RRR ) of 15%, which is very good, and as time goes by that rate improves. So, if Amarin announces the date that the 967th event is reached a calculation of Vascepa's effectiveness can be estimated, estimated because they do not know the placebo rate. So, it is an estimate but considering the diets of the subjects not being as high in fish consumption of the Japanese a range of 5% to 6% seems adequate. That is why it is not a certainty and an estimate.

  • Why would they share data in a DOUBLED blinded study?

  • Reply to

    Recuiting and Sharing

    by cyliu1222 22 hours ago

    Come on really?

  • Reply to

    Recuiting and Sharing

    by cyliu1222 22 hours ago

    I think we'll likely get another postponement on the 17th if whatever it is they're waiting for hasn't happened yet. I'm still speculating that a review of the interim data is underway or an agreed upon early look.

    We'll see.

  • If the study is futile, why recruiting more? So, certain efficacy has already been reached.

    If continuing the study is the best option, then "sharing available data now" doesn't do anything logically (except a pump and dump). "Undecided" is on scientific benefits and financial benefits.

    Be patient -- Feb 17th is coming.

  • Everyone: this post, like all others by this user, is designed to mislead by walking the reader down the least likely path of explanation while simultaneously remaining silent on the most likely.

    Amarin is "Undecided" because there are two conflicting exigencies at play. To their thinking, and mine, the only question is whether the data is good, or good enough, for an early stop to the trial. Should the data be good enough for an early stop management will be faced with a decision: agree to the stop and gain early approval or allow the trial to run to completion and negotiate a label change with the FDA while remaining mum on those results. This is what I believe the postponed 1st Amendment settlement is all about.

    This study (REDUCE-IT) is so vital to the scientific community, patients and their doctors, that Amarin might well elect, even from a strategic business perspective, to continue the study blinded thereby protecting its integrity.

    Make no mistake, there's validity to all perspectives expressed on this board and all biotechs are, by nature, a gamble. But a balanced assessment places less weight on this kind of speculation and more on science. And the science of Vascepa is clinically and consistently proven. Agenda driven erroneous conclusions are not.

  • Whether or not someone listens is not important. It is the attempt to manipulate investors which is the crime. I hope each one of these ahos keep going and as each one gets caught and prosecuted, I want new ahos to step in and take over the pump and dump project here. Just google prosecution of Yahoo stock board criminals. Law enforcement will not reveal their techniques so that the next aho to act up won't know how to avoid being caught.
    I know the share price keeps falling but - buy all you can! I know it was $18.00 and now is $1.27, but ignore all that. Keep buying! We have only suffered 4 years and have devastating losses to show for it, but if you hold another 2 years, there is a chance you might be able to get out of this stock with just huge losses. That is a respectable goal, right?
    You pumping criminal ahos will be caught.

  • They are saying that whenever the mid-term point is reached and Data is reviewed by the Data Monitoring Committee, Amarin is now (as of 2-8-16) undecided as to whether or not they want to share the Data Monitoring Committee's Data from the review with the public.

    Not a good look. Change made February 8, 2016? Why now?
    Now they are uncertain about sharing Data at mid-term?

    So when the study is told to continue through to the end (Dec 2017) Amarin isn't sure they want us to know anything from the mid-term analysis. Why would they feel the need to hide this from us?
    Are they anticipating bad news? If they were anticipating positive information, why would they (only now) state that they are not sure if they will share with the public?

    I guess it doesn't really matter.

    If the study is halted for futility, we will know Data. (very possible, but odds are against it) - 30% chance
    If the study is halted for overwhelming success, we will know Data (very highly unlikely) - 10% chance
    If the study is allowed to continue through the final 2 years, we will have a pretty good idea that the Data isn't particularly good (very highly likely) - 60% chance

    Everyone agrees that if Vascepa works, we will be able to tell by the mid-term of the study.
    If Vascepa works, they will be able to halt the study early.
    So, if we are told to continue the study, it essentially means Vascepa does not work, or does not work very well and we should allow the study to go through completion in order to see if there are any positive results that can be found after all patients are considered.

    Has Data Monitoring Committee Yes
    Plan to Share Data Undecided

  • I have to question your motives here centless. Are you a hired pumper? Per your own addmision this is an old article. Nobody here or in the medical world has questioned vascepas safety profile or effectiveness. What you have here up to this point is a case of a good drug doesn't always coralate into a selling drug or a good stock. That can't be argued. Sales have been paltry and quite frankly the stock has sucked for 3 years. You pumpers can't or won't look at at all angles because you are married and emotionally attached to this ticker. I have made several traded recently here at a gains even when the story has been bad because I know when to fold them. I can't understand for the life of me why you are posting these useless threads that are old and everyone already knows about other then some sort of agenda.

  • Do you have a source

  • Again, your reading comprehension is lacking. No one is talking about combo here. It is all in your mind, which is unable to concentrate on anything but what you you perceive is the topic, which is usually wrong. You angerly mumble to yourself constantly. I am afraid that I, one of your last responders, will no longer be able to discuss anything with you any longer because you allow yourself these hallucinations to control your mind as you drift off on these different tangents. Sorry, but it very frustrating trying to have a discussion with you. You need to find someone who gets paid to talk to you, a proffesional. I wish you well.

  • More important

Must Watch
AMRN
1.270.00(0.00%)Feb 12 4:00 PMEST